CA2447924C - Olopatadine formulations for topical administration - Google Patents

Olopatadine formulations for topical administration Download PDF

Info

Publication number
CA2447924C
CA2447924C CA002447924A CA2447924A CA2447924C CA 2447924 C CA2447924 C CA 2447924C CA 002447924 A CA002447924 A CA 002447924A CA 2447924 A CA2447924 A CA 2447924A CA 2447924 C CA2447924 C CA 2447924C
Authority
CA
Canada
Prior art keywords
solution
olopatadine
polyvinylpyrrolidone
composition
physical stability
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002447924A
Other languages
English (en)
French (fr)
Other versions
CA2447924A1 (en
Inventor
Ernesto J. Castillo
Wesley Wehsin Han
Huixiang Zhang
Haresh G. Bhagat
Onkar N. Singh
Joseph Paul Bullock
Suresh C. Dixit
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Alcon Pharmaceuticals Ltd
Novartis AG
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23162841&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2447924(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alcon Pharmaceuticals Ltd, Novartis AG, Alcon Inc filed Critical Alcon Pharmaceuticals Ltd
Publication of CA2447924A1 publication Critical patent/CA2447924A1/en
Application granted granted Critical
Publication of CA2447924C publication Critical patent/CA2447924C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002447924A 2001-06-27 2002-06-19 Olopatadine formulations for topical administration Expired - Lifetime CA2447924C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30131501P 2001-06-27 2001-06-27
US60/301,315 2001-06-27
PCT/US2002/019417 WO2003002093A1 (en) 2001-06-27 2002-06-19 Olopatadine formulations for topical administration

Publications (2)

Publication Number Publication Date
CA2447924A1 CA2447924A1 (en) 2003-01-09
CA2447924C true CA2447924C (en) 2009-11-03

Family

ID=23162841

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002447924A Expired - Lifetime CA2447924C (en) 2001-06-27 2002-06-19 Olopatadine formulations for topical administration

Country Status (20)

Country Link
US (2) US6995186B2 (https=)
EP (1) EP1399127B1 (https=)
JP (5) JP4827374B2 (https=)
KR (1) KR100884711B1 (https=)
CN (1) CN1211125C (https=)
AR (1) AR034619A1 (https=)
AT (1) ATE295149T1 (https=)
AU (1) AU2002310461B2 (https=)
BR (1) BRPI0210707B8 (https=)
CA (1) CA2447924C (https=)
DE (1) DE60204142T2 (https=)
DK (1) DK1399127T3 (https=)
ES (1) ES2238574T3 (https=)
GC (1) GC0000397A (https=)
MX (1) MXPA03011947A (https=)
PL (1) PL205565B1 (https=)
PT (1) PT1399127E (https=)
TW (1) TWI231759B (https=)
WO (1) WO2003002093A1 (https=)
ZA (1) ZA200308771B (https=)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100055152A1 (en) * 2008-08-26 2010-03-04 Trutek Corporation Antihistamine and antihistamine-like nasal application, products, and method
US7977376B2 (en) 2001-06-27 2011-07-12 Novartis Ag Olopatadine formulations for topical nasal administration
TWI231759B (en) * 2001-06-27 2005-05-01 Alcon Inc Olopatadine formulations for topical administration
US20050209312A1 (en) * 2004-03-19 2005-09-22 Bausch & Lomb Incorporated Carboxylic acid derivatives of doxepin formulations preserved with low-irritation preservative
US20070275853A1 (en) * 2004-04-08 2007-11-29 Kyowa Hakko Kogyo Co., Ltd. Solid Products with Improved Stability and Method for Producing the Same
US20070225356A1 (en) * 2004-04-21 2007-09-27 Kyowa Hakko Kogo Co., Ltd Preventive and/or Therapeutic Agent for Chronic Sinusitis
ZA200610350B (en) * 2004-06-28 2008-12-31 Alcon Inc Topical formulations for treating allergic diseases
AU2005309951B2 (en) * 2004-11-24 2011-07-07 Alcon, Inc. Method of delivering nasal spray
WO2006097458A1 (en) * 2005-03-15 2006-09-21 Nycomed Gmbh Novel combination
JP5315051B2 (ja) * 2005-07-08 2013-10-16 千寿製薬株式会社 オロパタジンを含む眼科用経皮吸収型製剤
US20070077302A1 (en) * 2005-09-30 2007-04-05 Azaam Alli Methods for stabilizing ophthalmic compositions
US20080114076A1 (en) * 2006-11-09 2008-05-15 Alcon Manufacturing Ltd. Punctal plug comprising a water-insoluble polymeric matrix
TWI409081B (zh) * 2006-11-09 2013-09-21 Alcon Res Ltd 用於藥物輸送之水不溶性聚合物基質
MX2009006146A (es) * 2006-12-18 2009-06-19 Alcon Res Ltd Dispositivos y metodos para la administracion de farmacos oftalmicos.
WO2008093358A2 (en) * 2007-01-29 2008-08-07 Sun Pharmaceutical Industries Limited Aqueous topical solution containing olopatadine
KR20100014858A (ko) * 2007-02-07 2010-02-11 알콘, 인코퍼레이티드 국소 비강 투여용 올로파타딘 제제
WO2008120249A1 (en) * 2007-03-30 2008-10-09 Sifi S.P.A. Pharmaceutical formulations based on apolar and polar lipids for ophthalmic use
TW200902025A (en) * 2007-04-11 2009-01-16 Alcon Res Ltd Use of an inhibitor of TNF α plus an antihistamine to treat allergic rhinitis and allergic conjunctivitis
EP2189157A4 (en) * 2007-09-06 2012-10-31 Kyowa Hakko Kirin Co Ltd EYE DROPPING WITH DIBENZO [b, e] OXEPINE DERIVATIVE
CA2723954A1 (en) * 2008-05-19 2009-11-26 Alcon Research, Ltd. Pharmaceutical compositions having carboxyvinyl polymer and povidone polymer
AU2009288566A1 (en) * 2008-08-26 2010-03-11 Trutek Corp. Electrostatically charged mask filter products and method for increased filtration efficiency
KR20110056526A (ko) * 2008-08-28 2011-05-30 트루텍 코프. 항히스타민 및 유사-항히스타민 코 외용약, 생성물 및 방법
US9458198B1 (en) 2009-06-26 2016-10-04 Shire Orphan Therapies Gmbh Cyclic peptide-based NPR-B agonists
EP2453872B1 (en) * 2009-07-17 2013-08-21 Alcon Research, Ltd. Olopatadine nasal spray regimen for children
WO2011027322A1 (en) 2009-09-03 2011-03-10 Ranbaxy Laboratories Limited Extended release dosage form containing olopatadine for oral administration
EP2480247B1 (en) * 2009-09-25 2020-02-12 Shire Orphan Therapies GmbH Novel npr-b agonists
US8551938B2 (en) * 2009-09-25 2013-10-08 Alcon Research, Ltd. NPR-B agonists
US20110082145A1 (en) * 2009-10-01 2011-04-07 Alcon Research, Ltd. Olopatadine compositions and uses thereof
AR078446A1 (es) 2009-12-18 2011-11-09 Alcon Res Ltd Agonistas de npr-b. uso.
WO2011075471A2 (en) 2009-12-18 2011-06-23 Alcon Research, Ltd. Novel npr-b agonists and methods of use for the treatment of c-type natriuretic peptide-mediated disorders
US20120022149A1 (en) * 2010-07-21 2012-01-26 Chowhan Masood A Pharmaceutical composition with enhanced solubility characteristics
EP2944319A1 (en) * 2010-11-08 2015-11-18 Arava Bio-Tech Ltd. Buffered ophthalmic compositions and use thereof
TWI544922B (zh) * 2011-05-19 2016-08-11 愛爾康研究有限公司 高濃度歐羅派特錠（ｏｌｏｐａｔａｄｉｎｅ）眼用組成物
CN102885767A (zh) * 2012-11-02 2013-01-23 江苏吉贝尔药业有限公司 一种新的盐酸奥洛他定滴眼液及其制备方法
EP3576770A1 (en) 2017-02-01 2019-12-11 Shire Human Genetic Therapies, Inc. Compounds and compositions for the treatment of ophthalmic disorders
JP7037349B2 (ja) * 2017-06-23 2022-03-16 参天製薬株式会社 水溶性粘稠化剤を含有する医薬組成物
WO2018235935A1 (ja) * 2017-06-23 2018-12-27 参天製薬株式会社 水溶性粘稠化剤を含有する医薬組成物
CN114980881A (zh) * 2019-12-06 2022-08-30 东兴药品工业株式会社 包含奥洛他定的鼻用组合物
US20230145529A1 (en) * 2020-03-31 2023-05-11 Santen Pharmaceutical Co., Ltd. Silver salt-containing ophthalmic aqueous composition filled in resin container
CN111700860A (zh) * 2020-07-09 2020-09-25 浙江尖峰药业有限公司 盐酸奥洛他定滴眼液及其制备方法
CN119318630B (zh) * 2024-10-16 2025-08-22 苏州欧康维视生物科技有限公司 一种阿托品药物组合物

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4370324A (en) 1980-09-17 1983-01-25 Bernstein Joel E Method and composition for treating and preventing irritation of the eyes
US4407791A (en) 1981-09-28 1983-10-04 Alcon Laboratories, Inc. Ophthalmic solutions
US4749700A (en) 1984-10-23 1988-06-07 Nastech Pharmaceutical Co, Inc. Novel methods of administering antihistamines, antinausea and antiemetic pharmaceutical agents and novel dosage forms containing same
US4923892A (en) 1985-08-17 1990-05-08 Burroughs Wellcome Co. Tricyclic aromatic compounds
GB8520662D0 (en) 1985-08-17 1985-09-25 Wellcome Found Tricyclic aromatic compounds
JPS6310784A (ja) 1986-03-03 1988-01-18 Kyowa Hakko Kogyo Co Ltd 抗アレルギー剤
ATE84968T1 (de) 1987-11-13 1993-02-15 Asta Medica Ag Azelastin enthaltende arzneimittel zur anwendung in der nase und/oder am auge.
IT1250691B (it) 1991-07-22 1995-04-21 Giancarlo Santus Composizioni terapeutiche per somministrazione intranasale comprendenti ketorolac.
JP3662944B2 (ja) 1993-08-24 2005-06-22 協和醗酵工業株式会社 点鼻剤
US5897858A (en) 1994-02-03 1999-04-27 Schering-Plough Healthcare Products, Inc. Nasal spray compositions exhibiting increased retention in the nasal cavity
US5641805A (en) 1995-06-06 1997-06-24 Alcon Laboratories, Inc. Topical ophthalmic formulations for treating allergic eye diseases
EP1014979A4 (en) 1997-06-09 2003-08-20 Bridge Pharma Inc CONNECTIONS WITH COMBINED ANTIHISTAMINIC AND FAST-CELL STABILIZING ACTIVITY FOR OPHTHALMOLOGICAL USE
WO2000003705A1 (en) 1998-07-14 2000-01-27 Alcon Laboratories, Inc. Use of 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid for the manufacture of a medicament for treating non-allergic ophthalmic inflammatory disorders and for the prevention of ocular neovascularization
US6146622A (en) 1998-10-27 2000-11-14 Alcon Laboratories, Inc. Use of certain anionic amino acid based surfactants to enhance antimicrobial effectiveness of topically administrable pharmaceutical compositions
DK1124535T3 (da) * 1998-10-27 2003-01-06 Alcon Lab Inc Konserverende system til topisk indgivelige farmaceutiske præparater indeholdende en fedtsyre/aminosyresæbe
US6274626B1 (en) * 1998-12-22 2001-08-14 Bausch & Lomb Incorporated Pheniramine-containing compositions and method for treating allergic responses
US6174914B1 (en) 1999-06-15 2001-01-16 Alcon Laboratories, Inc. Method of inhibiting cytokine release from human ocular cells
BR0014117A (pt) 1999-09-21 2002-05-14 Alcon Lab Inc Uso de sabÈes de acido graxo/aminoácido para aumentar a eficácia antimicrobiana de composições farmacêutica tópicas
MXPA02005007A (es) 1999-11-18 2004-08-12 Alcon Inc Uso de un antagonista h1 y un esteroide inocuo para tratar condiciones oculares.
DE60109742T2 (de) * 2000-01-25 2005-08-18 Alcon Inc. Antiallergische ophthalmische zubereitungen, geeignet zur anwendung mit kontaktlinsen
PE20020578A1 (es) 2000-10-10 2002-08-14 Upjohn Co Una composicion de antibiotico topico para el tratamiento de infecciones oculares
TWI231759B (en) * 2001-06-27 2005-05-01 Alcon Inc Olopatadine formulations for topical administration
BR0316203A (pt) 2002-11-12 2005-10-04 Alcon Inc Uso de um agente antialérgico e um esteróide para tratar rinite alérgica

Also Published As

Publication number Publication date
DK1399127T3 (da) 2005-06-13
BRPI0210707B1 (pt) 2015-08-04
BRPI0210707B8 (pt) 2021-05-25
GC0000397A (en) 2007-03-31
JP5328947B2 (ja) 2013-10-30
DE60204142D1 (de) 2005-06-16
ES2238574T3 (es) 2005-09-01
US7402609B2 (en) 2008-07-22
KR100884711B1 (ko) 2009-02-19
PT1399127E (pt) 2005-07-29
JP2010150292A (ja) 2010-07-08
PL205565B1 (pl) 2010-05-31
CN1525849A (zh) 2004-09-01
WO2003002093A1 (en) 2003-01-09
JP2004536096A (ja) 2004-12-02
JP2012107046A (ja) 2012-06-07
AR034619A1 (es) 2004-03-03
MXPA03011947A (es) 2004-03-26
US6995186B2 (en) 2006-02-07
JP4827374B2 (ja) 2011-11-30
KR20040025919A (ko) 2004-03-26
EP1399127A1 (en) 2004-03-24
ATE295149T1 (de) 2005-05-15
CN1211125C (zh) 2005-07-20
AU2002310461B2 (en) 2006-05-18
CA2447924A1 (en) 2003-01-09
JP2009114213A (ja) 2009-05-28
JP2013127005A (ja) 2013-06-27
PL367780A1 (en) 2005-03-07
TWI231759B (en) 2005-05-01
ZA200308771B (en) 2005-01-26
HK1059573A1 (en) 2004-07-09
BR0210707A (pt) 2004-07-20
DE60204142T2 (de) 2005-10-06
US20030055102A1 (en) 2003-03-20
US20050158387A1 (en) 2005-07-21
EP1399127B1 (en) 2005-05-11

Similar Documents

Publication Publication Date Title
CA2447924C (en) Olopatadine formulations for topical administration
AU2002310461A1 (en) Olopatadine formulations for topical administation
JP5901087B2 (ja) 点眼用水性組成物
US4425344A (en) Compositions for the treatment of glaucoma containing triamterene
RO115409B1 (ro) Compozitie oftalmica cu viscozitate scazuta
RO115410B1 (ro) Compozitie oftalmica
US9801813B2 (en) Preservative-free ophthalmic pharmaceutical formulation
JP2012533554A (ja) 小児のためのオロパタジン経鼻噴霧剤レジメン
JP2960507B2 (ja) 抗菌性組成物
JP3094233B2 (ja) （ｓ）−チモロール半水和物を含有する局所眼科治療用組成物及びその製造方法
HK1059573B (en) Olopatadine formulations for topical administration
CA2758858C (en) Aqueous ophthalmic compositions containing anionic therapeutic agents
CA2002552C (en) Pharmaceutical aqueous solution for ophthalmic use comprising a water solube pharmaceutically acceptable acid addition salt of ibopamine
KR20100032018A (ko) 항히스타민제를 포함하는 점안용 조성물

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20220620